Wilko Weichert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/545482/publications.pdf

Version: 2024-02-01

211 papers	7,699 citations	47006 47 h-index	76900 74 g-index
216 all docs	216 docs citations	216 times ranked	13637 citing authors

#	Article	IF	Citations
1	Targeted Î±-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding. Journal of Nuclear Medicine, 2017, 58, 1624-1631.	5.0	367
2	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathology, 2016, 29, 1165-1172.	5.5	340
3	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nature Genetics, 2017, 49, 65-74.	21.4	326
4	Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nature Communications, 2018, 9, 144.	12.8	197
5	NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discovery, 2018, 8, 1087-1095.	9.4	189
6	Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20%. Modern Pathology, 2017, 30, 587-598.	5.5	162
7	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell, 2016, 30, 75-91.	16.8	144
8	CD274/PD-L1gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget, 2016, 7, 12024-12034.	1.8	141
9	Precision oncology based on omics data: The NCT Heidelberg experience. International Journal of Cancer, 2017, 141, 877-886.	5.1	133
10	Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Modern Pathology, 2017, 30, 610-619.	5.5	131
11	R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Annals of Surgery, 2018, 268, 1058-1068.	4.2	126
12	Single-Nucleus and In Situ RNAâ€“Sequencing Reveal Cell Topographies in the Human Pancreas. Gastroenterology, 2021, 160, 1330-1344.e11.	1.3	112
13	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	2.5	102
14	Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Developmental Cell, 2018, 45, 696-711.e8.	7.0	96
15	Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Human Pathology, 2018, 77, 70-79.	2.0	95
16	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and realâ€life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	5.1	95
17	Classical pathology and mutational load of breast cancer â€“ integration of two worlds. Journal of Pathology: Clinical Research, 2015, 1, 225-238.	3.0	91
18	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. Oncotarget, 2014, 5, 8147-8160.	1.8	83

#	Article	IF	Citations
19	Single-Cell Analysis Uncovers Clonal Acinar Cell Heterogeneity in the Adult Pancreas. Developmental Cell, 2016, 39, 289-301.	7.0	82
20	Tumour budding activity and cell nest size determine patient outcome in oral squamous cell carcinoma: proposal for an adjusted grading system. Histopathology, 2017, 70, 1125-1137.	2.9	81
21	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clinical Cancer Research, 2018, 24, 351-359.	7.0	81
22	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations ofÂtheÂQuality in Pathology Study. Journal of Thoracic Oncology, 2020, 15, 1177-1189.	1.1	81
23	Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. Journal of Clinical Investigation, 2020, 130, 4704-4709.	8.2	80
24	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
25	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European Journal of Cancer, 2019, 106, 234-243.	2.8	75
26	Siteâ€toâ€Site Reproducibility and Spatial Resolution in MALDIâ€“MSI of Peptides from Formalinâ€Fixed Paraffinâ€Embedded Samples. Proteomics - Clinical Applications, 2019, 13, e1800029.	1.6	73
27	Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens. Molecular and Cellular Proteomics, 2016, 15, 3081-3089.	3.8	72
28	PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue â€“ prognostic implications and rationale for immunotherapy. OncoImmunology, 2018, 7, e1389366.	4.6	72
29	Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma. European Respiratory Journal, 2016, 47, 938-946.	6.7	69
30	Bcl10-controlled Malt1 paracaspase activity is key for the immune suppressive function of regulatory T cells. Nature Communications, 2019, 10, 2352.	12.8	68
31	Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nature Communications, 2019, 10, 1635.	12.8	64
32	Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epsteinâ€“Barr virus infection and highâ€•and lowâ€•microsatellite instability. Journal of Pathology: Clinical Research, 2019, 5, 227-239.	3.0	63
33	Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma. Journal of Immunology, 2019, 202, 278-291.	0.8	61
34	SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut, 2020, 69, 1472-1482.	12.1	61
35	SMARCA4-deficient Sinonasal Carcinoma. Head and Neck Pathology, 2017, 11, 541-545.	2.6	58
36	Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. BMC Medical Genomics, 2021, 14, 62.	1.5	58

#	Article	IF	Citations
37	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget, 2014, 5, 9952-9965.	1.8	58
38	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Journal of Physical Education and Sports Management, 2016, 2, a001180.	1.2	57
39	pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. European Journal of Cancer, 2017, 84, 121-129.	2.8	57
40	HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGFÎ²1 signalling in inflammation. Mucosal Immunology, 2019, 12, 656-667.	6.0	56
41	PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancerâ€"a randomised biomarker-driven clinical phase II AIO study. European Journal of Cancer, 2018, 92, 11-19.	2.8	55
42	A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging. European Radiology Experimental, 2019, 3, 41.	3.4	55
43	MALDI imaging mass spectrometry â€" From bench to bedside. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 776-783.	2.3	54
44	Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells. Clinical Cancer Research, 2020, 26, 220-231.	7.0	54
45	Immunohistochemical expression of CD44 in oral squamous cell carcinoma in relation to histomorphological parameters and clinicopathological factors. Histopathology, 2018, 73, 559-572.	2.9	52
46	Testing NTRK testing: Wetâ€lab and in silico comparison of RNAâ€based targeted sequencing assays. Genes Chromosomes and Cancer, 2020, 59, 178-188.	2.8	52
47	MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. European Journal of Cancer, 2017, 77, 3-12.	2.8	51
48	Levels of the Autophagy-Related 5 Protein Affect Progression and Metastasis of Pancreatic Tumors in Mice. Gastroenterology, 2019, 156, 203-217.e20.	1.3	50
49	In Vivo PET Imaging of the Cancer Integrin Î±vÎ²6 Using ⁶⁸Ga-Labeled Cyclic RGD Nonapeptides. Journal of Nuclear Medicine, 2017, 58, 671-677.	5.0	49
50	Isolation and characterization of circulating tumor cells using a novel workflow combining the CellSearch^{Â®} system and the CellCelector^{â„¢}. Biotechnology Progress, 2017, 33, 125-132.	2.6	48
51	MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2017, 162, 511-521.	2.5	48
52	A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy. PLoS ONE, 2019, 14, e0218642.	2.5	48
53	Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Gastroenterology, 2021, 160, 346-361.e24.	1.3	48
54	Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix. Journal of Pathology: Clinical Research, 2018, 4, 93-102.	3.0	47

#	Article	IF	Citations
55	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 599-608.	2.8	45
56	Pharmacoproteomic characterisation of human colon and rectal cancer. Molecular Systems Biology, 2017, 13, 951.	7.2	44
57	Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. Modern Pathology, 2018, 31, 829-839.	5.5	44
58	Clinicopathological Profiling of Lung Carcinoids with a Ki67 Index > 20%. Neuroendocrinology, 2019, 108, 109-120.	2.5	44
59	Synergistic effects of crizotinib and radiotherapy in experimental EML4â€“ALK fusion positive lung cancer. Radiotherapy and Oncology, 2015, 114, 173-181.	0.6	43
60	Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 409-418.	2.8	42
61	Tumor Budding and Cell Nest Size Are Highly Prognostic in Laryngeal and Hypopharyngeal Squamous Cell Carcinoma. American Journal of Surgical Pathology, 2019, 43, 303-313.	3.7	41
62	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors â€“ An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	2.8	41
63	Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. Oncotarget, 2017, 8, 46756-46768.	1.8	41
64	3D histopathology of human tumours by fast clearing and ultramicroscopy. Scientific Reports, 2020, 10, 17619.	3.3	39
65	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Nodeâ€“positive study. European Journal of Cancer, 2019, 114, 76-88.	2.8	37
66	Surgery of gastric cancer and esophageal cancer: Does age matter?. Journal of Surgical Oncology, 2015, 112, 387-395.	1.7	36
67	ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. Lung Cancer, 2015, 90, 465-471.	2.0	36
68	Establishment of a patient-derived orthotopic osteosarcoma mouse model. Journal of Translational Medicine, 2015, 13, 136.	4.4	35
69	MTOR inhibitor-based combination therapies for pancreatic cancer. British Journal of Cancer, 2018, 118, 366-377.	6.4	35
70	Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine, 2020, 9, 724.	2.4	35
71	MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus. Journal of Translational Medicine, 2018, 16, 109.	4.4	34
72	Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer. International Journal of Cancer, 2019, 145, 3299-3310.	5.1	34

#	Article	IF	Citations
73	NUT carcinoma of the thorax: Case report and review of the literature. Lung Cancer, 2015, 90, 484-491.	2.0	33
74	Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma. Epigenetics, 2016, 11, 780-790.	2.7	33
75	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	1.8	33
76	A new classification method for MALDI imaging mass spectrometry data acquired on formalin-fixed paraffin-embedded tissue samples. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 916-926.	2.3	32
77	MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nature Communications, 2020, 11, 4527.	12.8	32
78	Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 3616-3628.	7.0	31
79	Mutations in genes encoding <scp>PI3Kâ€AKT</scp> and <scp>MAPK</scp> signaling define anogenital papillary hidradenoma. Genes Chromosomes and Cancer, 2016, 55, 113-119.	2.8	29
80	Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma. Clinical Cancer Research, 2017, 23, 962-973.	7.0	29
81	Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. Genes Chromosomes and Cancer, 2016, 55, 268-277.	2.8	28
82	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Lung Cancer, 2020, 142, 114-119.	2.0	28
83	Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3Kâ€“AKT pathway. Genes Chromosomes and Cancer, 2017, 56, 11-17.	2.8	27
84	<scp>NTRK</scp> testing: First results of the <scp>QuiPâ€EQA</scp> scheme and a comprehensive map of <scp>NTRK</scp> fusion variants and their diagnostic coverage by targeted <scp>RNA</scp>â€based <scp>NGS</scp> assays. Genes Chromosomes and Cancer, 2020, 59, 445-453.	2.8	27
85	Mammary Analogue Secretory Carcinoma of Salivary Glands: Diagnostic Pitfall with Distinct Immunohistochemical Profile and Molecular Features. Rare Tumors, 2017, 9, 89-92.	0.6	26
86	Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1179-1187.	6.4	26
87	Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine Neoplasms. Neuroendocrinology, 2020, 110, 393-403.	2.5	26
88	Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer. British Journal of Cancer, 2017, 117, 220-226.	6.4	25
89	PET/CT imaging of head-and-neck and pancreatic cancer in humans by targeting the â€œCancer Integrinâ€•Î±vÎ²6 with Ga-68-Trivehexin. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1136-1147.	6.4	25
90	Perspective of Î±vÎ²6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions. Molecular Imaging, 2017, 16, 153601211770938.	1.4	24

#	Article	IF	Citations
91	Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer. PLoS ONE, 2017, 12, e0186847.	2.5	24
92	Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas. OncoImmunology, 2019, 8, 1614858.	4.6	24
93	PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. Medical Oncology, 2016, 33, 120.	2.5	23
94	Epithelial NEMO/IKKÎ³ limits fibrosis and promotes regeneration during pancreatitis. Gut, 2017, 66, 1995-2007.	12.1	23
95	Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information. Proteomics - Clinical Applications, 2019, 13, e1800035.	1.6	23
96	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group â€˜Molecular Diagnostics and Therapyâ€™. European Journal of Cancer, 2020, 135, 1-7.	2.8	23
97	A multicentre analytical comparison study of interâ€reader and interâ€assay agreement of four programmed deathâ€ligand 1 immunohistochemistry assays for scoring in tripleâ€negative breast cancer. Histopathology, 2021, 78, 567-577.	2.9	23
98	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23
99	Protein kinase C isoform expression in ovarian carcinoma correlates with indicators of poor prognosis. International Journal of Oncology, 2003, 23, 633-9.	3.3	23
100	CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. British Journal of Cancer, 2022, 126, 1470-1480.	6.4	23
101	Novel prognostic histopathological grading system in oral squamous cell carcinoma based on tumour budding and cell nest size shows high interobserver and intraobserver concordance. Journal of Clinical Pathology, 2019, 72, 285-294.	2.0	22
102	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes Chromosomes and Cancer, 2017, 56, 758-766.	2.8	21
103	New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma. Anticancer Research, 2020, 40, 3109-3118.	1.1	21
104	Loss of RNF43 Function Contributes to Gastric Carcinogenesis by Impairing DNA Damage Response. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1071-1094.	4.5	21
105	An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 359-368.	2.8	21
106	Typing of colon and lung adenocarcinoma by high throughput imaging mass spectrometry. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 858-864.	2.3	20
107	Identification of treatmentâ€induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Molecular Medicine, 2022, 14, e14876.	6.9	20
108	Prognostic impact of PD-1 and its ligands in renal cell carcinoma. Medical Oncology, 2017, 34, 99.	2.5	19

#	Article	IF	Citations
109	In MALDIâ€“Mass Spectrometry Imaging on Formalinâ€Fixed Paraffinâ€Embedded Tissue Specimen Section Thickness Significantly Influences m/z Peak Intensity. Proteomics - Clinical Applications, 2019, 13, e1800074.	1.6	19
110	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene, 2020, 39, 814-832.	5.9	19
111	Unraveling most abundant mutational signatures in head and neck cancer. International Journal of Cancer, 2021, 148, 115-127.	5.1	19
112	Proteomics in Pathology. Proteomics, 2018, 18, 1700361.	2.2	18
113	Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples. International Journal of Molecular Sciences, 2020, 21, 6407.	4.1	18
114	The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations. Cancer Immunology, Immunotherapy, 2021, 70, 1679-1689.	4.2	18
115	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. Medical Oncology, 2017, 34, 71.	2.5	17
116	Identification of MALDI Imaging Proteolytic Peptides Using LCâ€MS/MSâ€Based Biomarker Discovery Data: A Proof of Concept. Proteomics - Clinical Applications, 2019, 13, e1800158.	1.6	17
117	In vivo imaging of early stages of rheumatoid arthritis by Î±5Î²1-integrin-targeted positron emission tomography. EJNMMI Research, 2019, 9, 87.	2.5	17
118	Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy. Oncotarget, 2018, 9, 20747-20760.	1.8	17
119	Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer. Breast, 2021, 60, 238-244.	2.2	17
120	Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations. Lung Cancer, 2018, 126, 80-88.	2.0	16
121	Lymph node infiltration, parallel metastasis and treatment success in breast cancer. Breast, 2019, 48, 1-6.	2.2	16
122	Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC. British Journal of Cancer, 2020, 123, 288-297.	6.4	16
123	Significance of tumour regression in lymph node metastases of gastric and gastroâ€oesophageal junction adenocarcinomas. Journal of Pathology: Clinical Research, 2020, 6, 263-272.	3.0	16
124	Mesenchymal/non-epithelial mimickers of neuroendocrine neoplasms with a focus on fusion gene-associated and SWI/SNF-deficient tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 1209-1219.	2.8	16
125	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. Histopathology, 2019, 75, 312-319.	2.9	15
126	Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylinâ€“eosin-based morphologic parameters from the WHO classification. British Journal of Cancer, 2021, 125, 1632-1646.	6.4	15

#	Article	IF	Citations
127	Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiation Oncology, 2015, 10, 146.	2.7	14
128	Neoadjuvant image-guided helical intensity modulated radiotherapy of extremity sarcomas â€“ a single center experience. Radiation Oncology, 2019, 14, 2.	2.7	14
129	Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer. Cancers, 2020, 12, 1689.	3.7	14
130	CD57 Expression in Incidental, Clinically Manifest, and Metastatic Carcinoma of the Prostate. BioMed Research International, 2014, 2014, 1-9.	1.9	13
131	Universal Genomic Testing: The next step in oncological decision-making or a dead end street?. European Journal of Cancer, 2017, 82, 72-79.	2.8	13
132	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1443-1454.	4.2	13
133	Modeling and multiscale characterization of the quantitative imaging based fibrosis index reveals pathophysiological, transcriptome and proteomic correlates of lung fibrosis induced by fractionated irradiation. International Journal of Cancer, 2019, 144, 3160-3173.	5.1	13
134	Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results. Breast, 2020, 49, 101-107.	2.2	13
135	Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes. Cancers, 2020, 12, 2704.	3.7	13
136	Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters. Journal of Clinical Medicine, 2020, 9, 1250.	2.4	13
137	EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC â€“ Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIPÂ®). Pathology Research and Practice, 2017, 213, 1530-1535.	2.3	12
138	Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies. Seminars in Cancer Biology, 2022, 84, 3-15.	9.6	12
139	Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer. Cancer Discovery, 2021, 11, 3158-3177.	9.4	12
140	Evaluation of Disposable Trap Column nanoLCâ€“FAIMSâ€“MS/MS for the Proteomic Analysis of FFPE Tissue. Journal of Proteome Research, 2021, 20, 5402-5411.	3.7	12
141	Multicenter Evaluation of Tissue Classification by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. Analytical Chemistry, 2022, 94, 8194-8201.	6.5	12
142	Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Letters, 2016, 371, 326-333.	7.2	11
143	Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinoma. British Journal of Cancer, 2019, 121, 1050-1057.	6.4	11
144	Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma. British Journal of Cancer, 2020, 122, 835-846.	6.4	11

#	Article	IF	Citations
145	[18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Research, 2021, 11, 70.	2.5	11
146	Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 3969.	3.7	11
147	Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. Journal of Experimental Medicine, 2021, 218, .	8.5	11
148	A Mass Spectrometry Imaging Based Approach for Prognosis Prediction in UICC Stage I/II Colon Cancer. Cancers, 2021, 13, 5371.	3.7	11
149	Semiconductorâ€Based Sequencing of Formalinâ€Fixed, Paraffinâ€Embedded Colorectal Cancer Samples. Oncologist, 2015, 20, e10-1.	3.7	10
150	Clinical performance of an analytically validated assay in comparison to microarray technology to assess PITX2 DNA-methylation in breast cancer. Scientific Reports, 2018, 8, 16861.	3.3	10
151	Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network. Pathology, 2019, 51, 362-368.	0.6	10
152	Discerning the Primary Carcinoma in Malignant Peritoneal and Pleural Effusions Using Imaging Mass Spectrometryâ€"A Feasibility Study. Proteomics - Clinical Applications, 2019, 13, 1800064.	1.6	10
153	Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. Cancers, 2021, 13, 1048.	3.7	10
154	Prediction of Tumor Cellularity in Resectable PDAC from Preoperative Computed Tomography Imaging. Cancers, 2021, 13, 2069.	3.7	10
155	The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Lowâ€"Expressing CancerIn VitroandIn Vivo. Cancer Immunology Research, 2021, 9, 779-789.	3.4	10
156	Whole Exome Sequencing of Biliary Tubulopapillary Neoplasms Reveals Common Mutations in Chromatin Remodeling Genes. Cancers, 2021, 13, 2742.	3.7	10
157	Implementation of Mass Spectrometry Imaging in Pathology. Clinics in Laboratory Medicine, 2021, 41, 173-184.	1.4	9
158	MSI testing. Der Pathologe, 2021, 42, 110-118.	1.6	9
159	Diverse â€˜just-rightâ€™ levels of chromosomal instability and their clinical implications in neoadjuvant treated gastric cancer. British Journal of Cancer, 2021, 125, 1621-1631.	6.4	9
160	Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker?. Cancers, 2021, 13, 5111.	3.7	9
161	Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. , 2022, 10, e004115.		9
162	c-Met in chromophobe renal cell carcinoma. Medical Oncology, 2017, 34, 15.	2.5	8

#	Article	IF	Citations
163	Clinical Validation of PITX2 DNA Methylation to Predict Outcome in High-Risk Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy. Breast Care, 2018, 13, 425-433.	1.4	8
164	A microsatellite based multiplex PCR method for the detection of chromosomal instability in gastric cancer. Scientific Reports, 2018, 8, 12551.	3.3	8
165	Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological infiltration. PLoS ONE, 2019, 14, e0208717.	2.5	8
166	Pancreatic neuroendocrine tumors with somatostatin expression and paraganglioma-like features. Human Pathology, 2020, 102, 79-87.	2.0	8
167	Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. Journal of Cancer, 2020, 11, 6081-6089.	2.5	8
168	Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e629-e642.	1.9	8
169	The Impact of Histological Annotations for Accurate Tissue Classification Using Mass Spectrometry Imaging. Metabolites, 2021, 11, 752.	2.9	8
170	MALDI Mass Spectrometry Imagingâ€"Prognostic Pathways and Metabolites for Renal Cell Carcinomas. Cancers, 2022, 14, 1763.	3.7	8
171	Mature mediastinal teratoma with subtotal unidirectional pancreatic differentiation. Pathology Research and Practice, 2010, 206, 346-348.	2.3	7
172	BarrettNETâ€"a prospective registry for risk estimation of patients with Barrett's esophagus to progress to adenocarcinoma. Ecological Management and Restoration, 2019, 32, .	0.4	7
173	Combined DCE-MRI- and FDG-PET enable histopathological grading prediction in a rat model of hepatocellular carcinoma. European Journal of Radiology, 2020, 124, 108848.	2.6	7
174	Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma. , 2021, 9, e002754.		7
175	The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner. Oncogene, 2022, 41, 1376-1382.	5.9	7
176	Engineering a better light sheet in an axiconâ€based system using a flattened Gaussian beam of low order. Journal of Biophotonics, 2022, 15, e202100342.	2.3	7
177	MALDI Mass Spectrometry Imaging for the Distinction of Adenocarcinomas of the Pancreas and Biliary Tree. Molecules, 2022, 27, 3464.	3.8	7
178	First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer. Archives of Gynecology and Obstetrics, 2020, 302, 1461-1467.	1.7	6
179	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.	2.8	6
180	PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.. Journal of Clinical Oncology, 2019, 37, 4018-4018.	1.6	6

#	Article	IF	Citations
181	Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups. Cancers, 2021, 13, 6177.	3.7	6
182	Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patientsâ€™ prognosis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1109-1118.	2.5	5
183	Genetically Engineered Mouse Models of Liver Tumorigenesis Reveal a Wide Histological Spectrum of Neoplastic and Non-Neoplastic Liver Lesions. Cancers, 2020, 12, 2265.	3.7	5
184	Differential Effects of Trp53 Alterations in Murine Colorectal Cancer. Cancers, 2021, 13, 808.	3.7	5
185	uPAâ€PAIâ€1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils. EMBO Molecular Medicine, 2021, 13, e13110.	6.9	5
186	Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. Cancers, 2021, 13, 5182.	3.7	5
187	Bridging the Species Gap: Morphological and Molecular Comparison of Feline and Human Intestinal Carcinomas. Cancers, 2021, 13, 5941.	3.7	5
188	Tumour cell budding and spread through air spaces in squamous cell carcinoma of the lung â€“ Determination and validation of optimal prognostic cut-offs. Lung Cancer, 2022, 169, 1-12.	2.0	5
189	Early and late toxicity profiles of patients receiving immediate postoperative radiotherapy versus salvage radiotherapy for prostate cancer after prostatectomy. Strahlentherapie Und Onkologie, 2019, 195, 131-144.	2.0	4
190	Molecular characterization of hepatic epithelioid hemangioendothelioma reveals alterations in various genes involved in DNA repair, epigenetic regulation, signaling pathways, and cell cycle control. Genes Chromosomes and Cancer, 2020, 59, 106-110.	2.8	4
191	Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer. Journal of Cancer Research and Clinical Oncology, 2022, , .	2.5	4
192	Postâ€neoadjuvant assessment of tumour budding according to <scp>ITBCC</scp> subgroups delivers stageâ€and <scp>regressionâ€grade</scp> independent prognostic information in intestinalâ€type gastric adenocarcinoma. Journal of Pathology: Clinical Research, 0, , .	3.0	4
193	Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-NaÃ¯ve Patients with Resectable Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 3496.	3.7	3
194	Do Canine Pancreatic Neuroendocrine Neoplasms Resemble Human Pancreatic Neuroendocrine Tumours? A Comparative Morphological and Immunohistochemical Investigation. Journal of Comparative Pathology, 2020, 181, 73-85.	0.4	3
195	Correlation of in vivo imaging to morphomolecular pathology in translational research: challenge accepted. EJNMMI Research, 2021, 11, 83.	2.5	3
196	Aberrant <scp>DNA</scp> methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the <scp>CpG</scp> island methylator phenotype. International Journal of Cancer, 2022, 150, 617-625.	5.1	3
197	PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients. Breast Care, 2021, 16, 523-531.	1.4	3
198	Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma. EJNMMI Research, 2021, 11, 120.	2.5	3

#	Article	IF	Citations
199	Elevated microsatellite instability at selected tetranucleotide (<scp>EMAST</scp>) repeats in gastric cancer: a distinct microsatellite instability type with potential clinical impact?. Journal of Pathology: Clinical Research, 2022, 8, 233-244.	3.0	3
200	Circulating Tumor DNA Profiling of a Diffuse Large B Cell Lymphoma Patient with Secondary Acute Myeloid Leukemia. Cancers, 2022, 14, 1371.	3.7	3
201	Comparative Study of the Role of Interepithelial Mucosal Mast Cells in the Context of Intestinal Adenoma-Carcinoma Progression. Cancers, 2022, 14, 2248.	3.7	3
202	Assessing homologous recombination deficiency (HRD) in ovarian cancer: Optimizing concordance of the regulatory-approved companion diagnostic and a next-generation sequencing (NGS) assay kit.. Journal of Clinical Oncology, 2022, 40, e17571-e17571.	1.6	3
203	Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia. Journal of Physical Education and Sports Management, 2016, 2, a001123.	1.2	2
204	Generation of ductal organoids from normal mammary luminal cells reveals invasive potential. Journal of Pathology, 2021, 255, 451-463.	4.5	2
205	Diagnostic PD-L1 immunohistochemistry in NSCLC: Results of the first German harmonization study.. Journal of Clinical Oncology, 2016, 34, 3028-3028.	1.6	2
206	Immune-related gene expression signatures as predictive biomarkers for outcome after concurrent chemoradiation in patients with locally advanced oropharyngeal carcinomas.. Journal of Clinical Oncology, 2016, 34, 6056-6056.	1.6	0
207	Interlaboratory-concordance of PD-L1 IHC for NSCLC.. Journal of Clinical Oncology, 2017, 35, e20508-e20508.	1.6	0
208	Still a hopeless case for personalized oncology? Pancreatic cancer revisited. Oncoscience, 2018, 6, 285-286.	2.2	0
209	Clonal tumor evolution under induction chemotherapy and concurrent radiochemotherapy (RCHT) in patients with resectable stage IIIA (N2) and selected IIIb non-small cell lung cancer (NSCLC): Molecular analysis of the ESPATUE randomized phase III trial.. Journal of Clinical Oncology, 2019, 37, 8543-8543.	1.6	0
210	Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer. Cancer Research, 2022, 82, PD9-07-PD9-07.	0.9	0
211	Abstract 4018: Long-term response to Trastuzumab in patients with advanced gastric or gastroesophageal adenocarcinoma - A retrospective study. Cancer Research, 2022, 82, 4018-4018.	0.9	0